In an inducible lung adenocarcinoma mouse model, vaccination using the G12D KRAS mutations as neoantigens and a novel synthetic long peptide-containing cationic lipoplex-based delivery platform stimulated both CD4+ and CD8+ T cell response and suppressed tumor growth, while combination with checkpoint inhibitor furthered such suppression (179). The gene discussed is CD8A; the disease is neoplasm.